Kornimate/medical-research-clean huggingface dataset:
better pediatric asthma outcomes through chronic care

Conditions: Asthma

Summary: this 3-year, multi-site study focuses on the translation of cost-effective methods to bring a chronic care model to the care of poor, minority, inner-city children with asthma, at risk of the worst outcomes for the leading chronic disease of children. the specific aims are to: 1. develop a computer support system to deliver peer-driven, patient-linked guideline prompts at the point of care using affordable information technology; 2. evaluate the effect of the guideline prompt system on the process and outcomes (symptom control, health-related-quality-of-life, ed and hospitalizations) of asthma care; and 3. evaluate the added effect on outcomes of family-focused, supportive education delivered by a community health worker. the key product of the computer support system is a guideline prompt that serves as the mechanism for integrating patient specific data with standards of care. 548 children, ages 5-18, with physician diagnosed asthma, enrolled in one medicaid managed care organization in ct, and receiving care at one of four federally qualified community health centers will be recruited. all sites will have access to the computer support system and the to-be-developed, guideline-driven clinical standards of asthma care. in phase i (12 months), the effect of prompts delivered at the point of care on patient outcomes will be compared to the effect of no-prompt care. in phase ii (6 months), the effect of family-focused, supportive education will be assessed in combination with prompted care compared to no-prompt care and compared to no education. all patients will receive standard screening and outreach to keep appointments. data will be obtained from medical records, medical and pharmacy claims data as well as patient and parent interviews at baseline and quarterly for 18 months.


Eligibility criteria:
inclusion criteria: * determined by provider to be asthmatic * member of medical managed care organization partner group exclusion criteria: -

Keywords: pediatric asthma translational research health information technology
the study of effect of chronomodulated chemotherapy on the dendritic cells subsets in the treatment of advanced nasopharyngeal cancer

Conditions: Locally Advanced Head and Neck Squamous Cell Carcinoma

Summary: this study is to observe and compare the effect of docetaxel plus lobaplatin induction chemotherapy combined with lopoplatin chemoradiotherapy and tpf induction chemotherapy combined with cisplatin chemoradiotherapy on dendritic cells subsets in the treatment of locally advanced head and neck squamous cell carcinoma.

tpf program is currently the local advanced head and neck squamous cell carcinoma commonly used inducing chemotherapy, cisplatin is the preferred drug for the same period chemotherapy.dendritic cells (dc) play an essential role in the induction and regulation of immune responses.the effect of radiation and chemotherapy is closely related to the patients' immune function.in this study, phase ii clinical trials were performed. patients with locally advanced head and neck squamous cell carcinoma were randomly divided into experimental group and control group. the trial group was treated with docetaxel + lorosine-induced chemotherapy combined with lorplatin concurrent radiotherapy and chemotherapy. the control group was treated with tpf cisplatin concurrent chemotherapy, observed the relationship between dendritic cells subsets and clinical prognosis of patients, to provide a new method for the treatment of locally advanced nasopharyngeal carcinoma and technical support

Eligibility criteria:
inclusion criteria: 1. initial treatment of advanced nasopharyngeal carcinoma ⅲ-ⅳ patients with pathologically confirmed (according to 2010 uicc staging, t3-4, n0-3), without evidence of distant metastasis (m0). have measurable tumor lesions. 2. kps≥70 points. 3. the age of 18-70 years old, male or female. 4. no major organ dysfunction; normal bone marrow function (wbc ≥4.0 × 109 / l, platelets ≥100 × 109 / l, hemoglobin ≥90g / l), normal liver function (total bilirubin, alanine aminotransferase, aspartate aminotransferase ≤1.5 times the upper limit of normal), normal renal function (creatinine ≤ 1.5 times upper limit of normal). 5. understand this study and signed informed consent exclusion criteria: 1. three months in the use of chinese herbal medicine or immune modulators 2. distant metastasis. 3. who had received prior chemotherapy. 4. patients have physical or mental illness, and by researchers believe that patients can not be completely or fully understood in this study possible complications. 5. pregnancy (via the urine or serum β-hcg test confirmed) or during lactation. serious complications, such as uncontrolled hypertension, heart failure, diabetes and so on.

Keywords: npc peripheral blood dendritic cell chronic-chemotherap
comparison of intralesional triamcinolone versus verapamil for keloid treatment

Conditions: Keloid Scars

Summary: this study aims to compare the efficacy of intralesional triamcinolone and verapamil in patients presenting with keloid at our local setting. the results will guide us towards better management of keloids by choosing the more appropriate treatment. adequate treatment will reduce significant emotional and physical distress in patients. we hypothesized that mean reduction in vancouver scar score is higher in triamcinolone acetonide group compared to verapamil after three months of treatment.


Eligibility criteria:
inclusion criteria: * size of keloid1-5 cm, * on any site of the body, * duration less then five years and * baseline vancouver scar score of more the or equal to 5 exclusion criteria: * pregnant or lactating women, * family history of keloids, * acromegaly, and * congestive cardiac diseases

Keywords: keloid vancouver scar scale triamcinolone verapamil intralesional injection
efficacy and safety of iqp-vv-102 in weight management

Conditions: Obesity; Overweight

Summary: subjects are randomized to either iqp-vv-102 or a matching placebo. over 12 weeks, the subjects' body weight, body fat and safety parameters are monitored


Eligibility criteria:
inclusion criteria: * age 18 to 60 years * 25 kg/m2 ≤ bmi ≤ 35 kg/m2 * written informed consent exclusion criteria: * known sensitivity to sources of the active ingredients and excipients * pregnancy or nursing * inability to comply with study requirements, e.g. due to language difficulties * participation in another study during the last 30 days of the screening visit
rectus muscle re-approximation at cesarean delivery

Conditions: Post Cesarean Section Pain

Summary: we include in our study 200 pregnant women, primigravidas, at term who underwent elective lower segment cesarean section for the first time among the age group of 20 - 35 years. the patients are divided randomly into two groups as follows: * group (a): undergoing rectus muscle re-approximation * group (b): not undergoing rectus muscle re-approximation

we include in our study 200 pregnant women, primigravidas, at term who underwent elective lower segment cesarean section for the first time among the age group of 20 - 35 years. the patients are divided randomly into two groups as follows: * group (a): undergoing rectus muscle re-approximation * group (b): not undergoing rectus muscle re-approximation * examination for diastasis recti abdominis is done for all included patients before delivery, at 6 weeks, and 6 months postpartum. the women are tested in a standardized supine position with arms crossed over the chest. they are instructed to perform an abdominal crunch till the shoulder blades are off the bench. then we measure the inter-recti distance. if there is no separation or separation ˂ 2 finger breadths so, there is no diastasis recti abdominis. but if the separation is more than 2 finger breadths or more than 4.5 cm so, this is considered diastasis recti abdominis. the same surgical techniques are used for both groups. all women underwent pfnannenstiel incision under general or spinal anaesthesia, with a combination of sharp and blunt dissection to open the abdomen. the rectus muscles are dissected off the fascia, and the muscles are separated in the midline by pulling. then the uterus is opened followed by fetal and placental extraction. the transverse lower uterine segment incision is closed in two layers of continuous vicryl number 1 suture. the parietal peritoneum is closed using a continuous absorbable suture. in group (a): rectus muscle re-approximation is done by 3 interrupted sutures, but muscle is not closed in the other group. the rectus sheath is sutured using continuous absorbable sutures. finally, skin is sutured with subcuticular sutures with vicryl rapide.

Eligibility criteria:
inclusion criteria: * primigravida * undergoing elective cesarean section exclusion criteria: * patients with history of any pelvic or abdominal surgery those having any medical disorder with pregnancy patients with bmi ≥ 40 chronic analgesia use multiple pregnancies
effectiveness of treatment with tofacitinib in patients with psoriatic arthritis in routine clinical practice

Conditions: Psoriatic Arthritis

Summary: this is a multinational study of tofacitinib in patients treated for psoriatic arthritis in order to evaluate the effectiveness of treatment with tofacitinib on disease activity, remission, and quality of life, in a real-world setting over a 12-month observation period


Eligibility criteria:
inclusion criteria: patients must meet all of the following inclusion criteria to be eligible for inclusion in the study: 1. patients aged ≥ 18 years 2. moderate to severe psa disease activity diagnosed 3. patients for whom the physician's decision has been made to initiate treatment with tofacitinib, in usual clinical practice conditions and in compliance with the local label 4. patients are treatment naïve to tofacitinib on the date of providing informed consent 5. evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study 6. patients on dmards must have not had a treatment change in the past 3 months exclusion criteria: patients meeting any of the following criteria will not be included in the study: 1. contraindications according to the xeljanz® (tofacitinib) prescribing information 2. receipt of any investigational drug within 3 months before study inclusion 3. patient is pregnant or breastfeeding 4. recent herpes zoster infection (within past 6 months) or history of severe disseminated herpes zoster infection 5. active treatment for a malignancy 6. concomitant treatment with a biological disease-modifying antirheumatic drugs (bdmard)
hbot global functioning after stroke

Conditions: Stroke

Summary: stroke is one of the leading causes of disability and death in north america and europe. up to 30% of stroke survivors never recuperate completely and suffer from loss of function and poor quality of life. to improve recovery after stroke, innovative interventions should be a priority. hyperbaric oxygen therapy (hbot) is an intermittent inhalation of 100% oxygen in a hyperbaric chamber at a pressure higher than 1 absolute atmosphere (ata). there is a growing body of evidence that hbot can enhance ability of brain to changes its structure (neuroplasticity) in order to recover. exercise program during hbot can augment the effect. although, recent randomized controlled trials in patients with chronic brain injury showed promising results, there are no studies demonstrating combine effect hbot and exercise rehabilitation program on stroke recovery. the proposed study investigates feasibility, safety and efficacy of using a combination of hbot and exercise program to improve arm function recovery in chronic stroke patients. in this pilot randomized control trial, investigators will compare the combination of hbot and the focused rehabilitation exercise program versus exercise program alone on recovery of arm function in patients with chronic stroke.


Eligibility criteria:
inclusion criteria: * age \> 18 years * history of ischemic or hemorrhagic stroke 6-48 months confirmed by ct * arm hemiparesis/hemiplegia * chedoke-mcmaster stroke assessment scale 3-6 * ability to follow verbal commands exclusion criteria: * women with positive pregnancy test or plans to become pregnant during the study period * severe cognitive dysfunction (the mini mental state examination \<24 ) * claustrophobia * seizure disorder * active asthma * severe chronic obstructive pulmonary disease * history of spontaneous pneumothorax * history of severe congestive heart failure with left ventricular ejection fraction \< 30%; unstable angina * myocardial infarction (within the last 3 months) * chronic sinusitis * chronic acute otitis media or major ear drum trauma * current treatment with bleomycin, cisplatin, doxorubicin and disulfiram * participation in another investigative drug or device trial currently or within the last 30 days

Keywords: hyperbaric oxygen treatment, rehabilitation
using 3d kidney model based on artificial intelligence to assist partial nephrectomy: a prospective validation study

Conditions: Renal Cell Cancer

Summary: the goal of this study is to develop a real-time artificial intelligence-driven 3d kidney model to assist robotic or laparoscopic partial nephrectomy: • can this ai-powered model optimize the workflow of partial nephrectomy and enhance surgical benefits?

this study aims to evaluate the feasibility of the ai-based real-time image-guided kidney model system in optimizing partial nephrectomy workflows. patients scheduled for laparoscopic or robotic-assisted partial nephrectomy will be randomized to receive either ai-assisted surgical navigation (utilizing intraoperative 3d model overlay with automated registration) or conventional approaches. comparative metrics will include ischemia time, margin positivity rate, and operative efficiency indices. findings will inform iterative refinement of the system architecture based on clinical performance feedback.

Eligibility criteria:
inclusion criteria: * ages 18-80 years, regardless of gender * written informed consent obtained from the patient or legally authorized representative after full protocol disclosure * preoperative imaging (ct/mri) confirming clinical stage t1a or select t1b renal tumors suitable for partial nephrectomy (r.e.n.a.l. nephrometry score ≤10) * localized renal tumors without lymph node/distant metastasis per nccn guidelines® (v2023) * elective minimally invasive partial nephrectomy (laparoscopic/robotic) after comprehensive surgical counseling exclusion criteria: * multifocal renal tumors (bilateral or unilateral) * prior systemic anticancer therapy (targeted agents/immunotherapy/chemotherapy) within 6 months * absolute surgical contraindications (e.g., asa class ≥iv, uncontrolled coagulopathy) * intraoperative conversion to radical nephrectomy or open approach * postoperative adjuvant therapy during protocol-defined follow-up (12 months) * major comorbidities (e.g., nyha class iii/iv heart failure, egfr \<30 ml/min/1.73m²) affecting outcome assessment * concurrent enrollment in interventional clinical trials * investigator-determined ineligibility based on risk-benefit analysis

Keywords: partial nephrectomy articicial intelligence intraoperative real-time navigation
the influence of inhaled corticosteroids adherence on treatment response to mepolizumab in severe eosinophilic asthma

Conditions: Asthma; Eosinophilic

Summary: the study aim is to look at the effect of the regular use of inhaled corticosteroids on the response and received from mepolizumab treatment which you are receiving or had received before.

examine the outcomes of 250 patients who have been treated with mepolizumab within brsas and compare the adherence to ics in the responders and non-responder groups. if confirmed that non-adherence to ics was related to poor response to mepolizumab, steps then will be undertaken to better monitor and enhance adherence to ics to improve patients outcomes and response to mepolizumab treatment. this study will rely on retrospective analysis of medically existing data within the service ,the adherence to ics treatment will be measured using the prescription possession ratio "ppr" data is available in the patients' gp records and forms part of the routine clinical practice of the severe asthma clinic to monitor adherence to ics treatment. for a significant number of patients ,such data will be already available within patient medical records held at university hospitals birmingham nhs foundation trust (uhb), however missing data is expected and in such cases gp surgeries will be contacted to obtain the ppr. patients will be asked to agree to access to gp records as part of the informed consent process.

Eligibility criteria:
inclusion criteria: * patients of 18 years of age or higher * patients commenced on mepolizumab within the brsas network * patients who have at least 1 mepolizumab injection and with at least 3 months follow-up data from the time of treatment initiation * patients must be able and willing to give informed consent to participate in the study . an interpreter will be provided for those patients where english is not their first language. exclusion criteria: * refusal or inability to provide informed consent
evaluation of the tolerance of ceftaroline and ceftobiprole in the management of bji / pji

Conditions: Bone and Joint Infection; Antibiotic Reaction

Summary: staphyloccous aureus and coagulase negative staphylocci are responsible of a large marjority of pji. regarding the high rate of methicillin resistance, current guidelines recommend the use of a glycopeptide, and most frequently vancomycin, as the anti-gram positive agent in empirical therapy, while awaiting the microbiological results. vancomycin is not considered as a safe antibiotic, and daptomycin is frequently an alternative option. ceftaroline and ceftobiprole are the only betalactam active on methicillin-resistant staphylococci. as some data report a synergistic activity with daptomycin, they could be an option in pandrug-resistant staphylococci bji, but their use if off label in this indication.


Eligibility criteria:
inclusion criteria: * patients having had a pji or bji treated whith ceftaroline and/or ceftobiprole exclusion criteria: -

Keywords: bone and joint infection prosthesis joint infection adverse event ceftaroline ceftobiprole
predictive factors of the treatment failure in hepatitis c virus (hcv) infected patients treated with telaprevir

Conditions: Chronic Hepatitis C

Summary: the purpose of the study is to 1- detect and quantify hcv-pi resistant mutants with ultra-deep pyrosequencing (udps) technology, 2 - detect snps in p-glyocoprotein and cyp3a genes, in hcv mono-infected patients under/after telaprevir treatment.


Eligibility criteria:
inclusion criteria: * hcv mono-infected subjects * age \> 18 years exclusion criteria: * hbv co-infection

Keywords: hepatitis c direct antiviral agent (daa) ultra-deep pyrosequencing single polynucleotide polymorphisms treatment-resistant mutants hepatitis c virus protease inhibitor
gemcitabine monotherapy for metastatic breast cancer after anthracycline and taxane regimen

Conditions: Metastatic Breast Cancer

Summary: to investigate efficacy, safety and pk of gem monotherapy after prior chemotherapy with anthracycline and taxane regimen for patients with metastatic breast cancer


Eligibility criteria:
inclusion criteria: * histologically and/or cytologically confirmed breast cancer * received prior chemotherapy for metastatic breast cancer with anthracycline and taxane regimen * to have at least one measurable region * ps: 0-1 * to have adequate organ function (bone marrow, liver and renal function) exclusion criteria: * to have interstitial pneumonia or pulmonary fibrosis * to have inflammatory carcinoma * within 28 days after the latest chemotherapy or radiotherapy, 14 days after the latest hormonal/immunotherapy or 7 days after surgery * to have brain metastasis with symptom * to have severe complication (cardiac infarction, infection, drug hyper sensitivity or diabetes)

Keywords: after anthracycline taxane regimen
efficacy and tolerance of maintenance therapy in patients with incurable advanced colorectal cancer

Conditions: Incurable Colorectal Cancer; RAS-wild-type

Summary: 1. to evaluate efficacy, safety, and feasibility of maintenance therapy with cetuximab combined with irinotecan or fluorouracil after cetuximab plus irinotecan and fluorouracil(folfiri) in patients with incurable colorectal cancer. 2. the relevant phase iii studies reported that the progression free-survival of cetuximab combined with folfiri in advanced colorectal cancer was 4.3 months up to 6.8 months. this study assumed that the progression free-survival was 5.1 months which was not inferior to the continuous chemotherapy


Eligibility criteria:
inclusion criteria: 1. patients aged ≥18 years with histologically confirmed metastatic colorectal cancer 2. eastern cooperative oncology group performance status ≤2 and 3. life expectancy of \>3 months were enrolled. 4. all patients had to have at least one measurable lesion according to the response evaluation criteria in solid tumors (recist, version 1.1) 5. none was previous exposure to cetuximab or irinotecan . 6. patients had to have adequate haematological (absolute neutrophil count \>1.5 × 109/l; platelet count \>100 × 109/l; haemoglobin \>9 g/dl), hepatic \[total bilirubin \<1.5 × the upper limit of normal (uln); alanine aminotransferase and aspartate aminotransferase \<2.5 × uln, or \<5 × uln in the case of hepatic metastases or \<10 × uln in the case of osseous metastases; alkaline phosphatase \<2.5 × uln, or \<5 × uln or \<10 × uln in the case of hepatic or osseous metastases, respectively\] and renal function (creatinine clearance ≥60 ml/min) 7. all ras were wildtype. - exclusion criteria: 1. pregnant or breast-feeding women; 2. clinically significant cardiac disease; 3. lack of physical integrity of the upper gastrointestinal tract; 4. history of other malignancy; 5. central nervous system metastases. -

Keywords: incurable colorectal cancer maintenance therapy cetuximab
hyperimmune colostrum and oral mucositis

Conditions: Head and Neck Cancer

Summary: to study the effect of daily intake of hyperimmune colostrum on prevention and treatment of oral mucositis in patients with head and neck cancer undergoing high-dose radiation.


Eligibility criteria:
inclusion criteria: * patients with: naso-pharynx, oral cavity, oro-pharynx and advanced localized laryngeal cancer. exclusion criteria: * other tumors * non-epithelial tumors * pregnancy * poor functional status

Keywords: hyperimmune colostrum mucositis